Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $29.00

Zevra Therapeutics (NASDAQ:ZVRA - Free Report) had its price target upped by Cantor Fitzgerald from $25.00 to $29.00 in a research note published on Thursday,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities research analysts have also recently issued reports on ZVRA. HC Wainwright began coverage on Zevra Therapeutics in a research note on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price target for the company. Wall Street Zen upgraded Zevra Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. JMP Securities set a $18.00 target price on Zevra Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group boosted their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. Finally, Guggenheim increased their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, March 13th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Zevra Therapeutics currently has an average rating of "Buy" and a consensus target price of $23.71.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA traded up $0.51 during midday trading on Thursday, hitting $12.53. 1,626,224 shares of the company's stock were exchanged, compared to its average volume of 715,848. The company has a quick ratio of 2.93, a current ratio of 3.02 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $685.14 million, a PE ratio of -6.59 and a beta of 1.97. Zevra Therapeutics has a 12 month low of $5.45 and a 12 month high of $12.55. The company's 50 day moving average price is $9.06 and its 200 day moving average price is $8.20.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.15. The firm had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. During the same period last year, the business posted ($0.40) earnings per share. As a group, analysts predict that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZVRA. BNP Paribas Financial Markets purchased a new position in Zevra Therapeutics in the fourth quarter worth $53,000. GAMMA Investing LLC raised its stake in shares of Zevra Therapeutics by 20,564.1% during the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock worth $60,000 after purchasing an additional 8,020 shares during the period. Strs Ohio purchased a new position in shares of Zevra Therapeutics in the 1st quarter worth about $125,000. Squarepoint Ops LLC grew its position in Zevra Therapeutics by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after buying an additional 4,384 shares during the period. Finally, ProShare Advisors LLC bought a new position in Zevra Therapeutics during the fourth quarter valued at about $145,000. Hedge funds and other institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.